Eli Lilly and Company News - February 27, 2026

Eli Lilly Oral GLP-1 Beats Novo Nordisk Rival in Phase 3 Trial Amid Tolerability Concerns

Eli Lilly's oral GLP-1 candidate, orforglipron, demonstrated superior efficacy compared to Novo Nordisk's Rybelsus in a head-to-head Phase 3 trial for adults...

Eli Lilly Wins Major Biotech Licensing Dispute, Avoiding $278M Payout

Eli Lilly won a licensing dispute regarding an alleged breach of agreement. The company avoided a $278 million payout. The verdict removes financial...